We built what we wished existed.
Springboard was born out of a stark realization in Germany's ecosystem: there was a profound disconnect between the capital supporting early-stage health tech and the domain intelligence required to actually scale it.
We saw brilliant scientific founders struggling to communicate their value to generalist investors, and we saw investors eager to deploy capital but lacking the clinical and regulatory foresight required to accurately assess deep health innovation.
So, we brought together operators, clinicians, and scientists to forge something different. A syndicate that speaks both the language of capital and the language of the lab.
What We Believe
Startups are the best vehicle for translating science into patient impact.
Academia discovers, but startups scale. Commercial viability is the ultimate prerequisite for widespread clinical utilization and systemic health reform.
Health tech needs investors who speak the language.
Clinically, scientifically, and commercially. Generalist advice falls short when navigating regulatory approvals, reimbursement strategies, or complex trial designs.
The best returns come from backing founders early.
By deploying capital and our operational intelligence at the seed and pre-seed stage, we de-risk the venture for downstream capital and maximize our compounding impact.
Leadership
Dr. Yonathan Goldwasser
MD, Managing Director
Leading strategy and operations, Yoni combines deep medical expertise with active VC investment experience. Building out the group's AI strategy.
Dr. Andreas Schmidt
MD, Managing Director
Spearheading partnerships, marketing, and fundraising, Andreas brings extensive domain experience linking scientific innovation with institutional investment scaling.
In Partnership with
